UniProt ID | TGFA1_HUMAN | |
---|---|---|
UniProt AC | Q8WUH2 | |
Protein Name | Transforming growth factor-beta receptor-associated protein 1 | |
Gene Name | TGFBRAP1 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 860 | |
Subcellular Localization | Cytoplasm . Early endosome . Colocalizes with TGF-beta receptors in the absence of signaling. | |
Protein Description | Plays a role in the TGF-beta/activin signaling pathway. It associates with inactive heteromeric TGF-beta and activin receptor complexes, mainly through the type II receptor, and is released upon activation of signaling. May recruit SMAD4 to the vicinity of the receptor complex and facilitate its interaction with receptor-regulated Smads, such as SMAD2.; Plays a role in vesicle-mediated protein trafficking of the endocytic membrane transport pathway. Believed to act as a component of the putative CORVET endosomal tethering complexes which is proposed to be involved in the Rab5-to-Rab7 endosome conversion probably implicating MON1A/B, and via binding SNAREs and SNARE complexes to mediate tethering and docking events during SNARE-mediated membrane fusion. The CORVET complex is proposed to function as a Rab5 effector to mediate early endosome fusion probably in specific endosome subpopulations. [PubMed: 25266290 Functions predominantly in APPL1-containing endosomes and in degradative but not recycling trafficking of endocytosed cargo] | |
Protein Sequence | MMSIKAFTLVSAVERELLMGDKERVNIECVECCGRDLYVGTNDCFVYHFLLEERPVPAGPATFTATKQLQRHLGFKKPVNELRAASALNRLLVLCDNSISLVNMLNLEPVPSGARIKGAATFALNENPVSGDPFCVEVCIISVKRRTIQMFLVYEDRVQIVKEVSTAEQPLAVAVDGHFLCLALTTQYIIHNYSTGVSQDLFPYCSEERPPIVKRIGRQEFLLAGPGGLGMFATVAGISQRAPVHWSENVIGAAVSFPYVIALDDEFITVHSMLDQQQKQTLPFKEGHILQDFEGRVIVATSKGVYILVPLPLEKQIQDLLASRRVEEALVLAKGARRNIPKEKFQVMYRRILQQAGFIQFAQLQFLEAKELFRSGQLDVRELISLYPFLLPTSSSFTRSHPPLHEYADLNQLTQGDQEKMAKCKRFLMSYLNEVRSTEVANGYKEDIDTALLKLYAEADHDSLLDLLVTENFCLLTDSAAWLEKHKKYFALGLLYHYNNQDAAAVQLWVNIVNGDVQDSTRSDLYEYIVDFLTYCLDEELVWAYADWVLQKSEEVGVQVFTKRPLDEQQKNSFNPDDIINCLKKYPKALVKYLEHLVIDKRLQKEEYHTHLAVLYLEEVLLQRASASGKGAEATETQAKLRRLLQKSDLYRVHFLLERLQGAGLPMESAILHGKLGEHEKALHILVHELQDFAAAEDYCLWCSEGRDPPHRQQLFHTLLAIYLHAGPTAHELAVAAVDLLNRHATEFDAAQVLQMLPDTWSVQLLCPFLMGAMRDSIHARRTMQVALGLARSENLIYTYDKMKLKGSSIQLSDKKLCQICQNPFCEPVFVRYPNGGLVHTHCAASRHTNPSSSSPGTRT | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
3 | Phosphorylation | -----MMSIKAFTLV -----CCCHHHHHHH | 21.46 | 24043423 | |
8 | Phosphorylation | MMSIKAFTLVSAVER CCCHHHHHHHHHHHH | 30.98 | 24043423 | |
11 | Phosphorylation | IKAFTLVSAVERELL HHHHHHHHHHHHHHH | 29.70 | 24043423 | |
76 | Ubiquitination | LQRHLGFKKPVNELR HHHHCCCCCCHHHHH | 55.13 | - | |
77 | Ubiquitination | QRHLGFKKPVNELRA HHHCCCCCCHHHHHH | 52.52 | 29967540 | |
112 | Phosphorylation | LNLEPVPSGARIKGA CCCCCCCCCCEEECE | 45.37 | - | |
210 | Ubiquitination | PYCSEERPPIVKRIG HHCCCCCCCCHHHHC | 26.67 | 22817900 | |
220 | Ubiquitination | VKRIGRQEFLLAGPG HHHHCCCEEEECCCC | 36.58 | 24816145 | |
234 | Phosphorylation | GGLGMFATVAGISQR CCCHHHHHHHCCCCC | 10.30 | 24043423 | |
239 | Phosphorylation | FATVAGISQRAPVHW HHHHHCCCCCCCCCC | 16.82 | 24043423 | |
281 | Phosphorylation | LDQQQKQTLPFKEGH CHHHHHCCCCCCCCC | 43.35 | 28060719 | |
285 | Ubiquitination | QKQTLPFKEGHILQD HHCCCCCCCCCEEEC | 61.93 | - | |
334 | Ubiquitination | EEALVLAKGARRNIP HHHHHHHHHHHCCCC | 49.28 | 27667366 | |
344 | Ubiquitination | RRNIPKEKFQVMYRR HCCCCHHHHHHHHHH | 47.42 | - | |
370 | Ubiquitination | QLQFLEAKELFRSGQ HHHHHHHHHHHHCCC | 45.64 | 30230243 | |
385 | Phosphorylation | LDVRELISLYPFLLP CCHHHHHHHHCHHCC | 34.18 | - | |
393 | Phosphorylation | LYPFLLPTSSSFTRS HHCHHCCCCCCCCCC | 41.01 | 28348404 | |
394 | Phosphorylation | YPFLLPTSSSFTRSH HCHHCCCCCCCCCCC | 23.26 | 28348404 | |
395 | Phosphorylation | PFLLPTSSSFTRSHP CHHCCCCCCCCCCCC | 31.76 | 27251275 | |
396 | Phosphorylation | FLLPTSSSFTRSHPP HHCCCCCCCCCCCCC | 30.33 | 28348404 | |
398 | Phosphorylation | LPTSSSFTRSHPPLH CCCCCCCCCCCCCHH | 32.96 | 28348404 | |
407 | Phosphorylation | SHPPLHEYADLNQLT CCCCHHHHCCHHHCC | 8.48 | 27642862 | |
437 | Phosphorylation | SYLNEVRSTEVANGY HHHHHHHCHHHHCCC | 33.81 | - | |
438 | Phosphorylation | YLNEVRSTEVANGYK HHHHHHCHHHHCCCH | 24.74 | - | |
444 | Phosphorylation | STEVANGYKEDIDTA CHHHHCCCHHCHHHH | 15.83 | - | |
445 | Ubiquitination | TEVANGYKEDIDTAL HHHHCCCHHCHHHHH | 50.76 | 29967540 | |
563 | Ubiquitination | VGVQVFTKRPLDEQQ HCCEEEECCCCCHHH | 40.32 | 29967540 | |
571 | Ubiquitination | RPLDEQQKNSFNPDD CCCCHHHHHCCCHHH | 55.01 | 29967540 | |
584 | Ubiquitination | DDIINCLKKYPKALV HHHHHHHHHCHHHHH | 53.08 | 29967540 | |
593 | Phosphorylation | YPKALVKYLEHLVID CHHHHHHHHHHHHHC | 15.16 | - | |
601 | Ubiquitination | LEHLVIDKRLQKEEY HHHHHHCHHHCCHHH | 43.83 | - | |
630 | Acetylation | QRASASGKGAEATET HHHHHCCCCHHHHHH | 53.07 | 26051181 | |
630 | Ubiquitination | QRASASGKGAEATET HHHHHCCCCHHHHHH | 53.07 | 22817900 | |
640 | Ubiquitination | EATETQAKLRRLLQK HHHHHHHHHHHHHHH | 32.48 | 24816145 | |
647 | Ubiquitination | KLRRLLQKSDLYRVH HHHHHHHHCCHHHHH | 46.00 | - | |
783 | Phosphorylation | DSIHARRTMQVALGL HHHHHHHHHHHHHHH | 13.35 | 24719451 | |
793 | Phosphorylation | VALGLARSENLIYTY HHHHHHCCCCEEEEE | 25.81 | 24719451 | |
798 | Phosphorylation | ARSENLIYTYDKMKL HCCCCEEEEEECCCC | 11.47 | 27762562 | |
799 | Phosphorylation | RSENLIYTYDKMKLK CCCCEEEEEECCCCC | 20.46 | 24719451 | |
800 | Phosphorylation | SENLIYTYDKMKLKG CCCEEEEEECCCCCC | 9.15 | 27762562 | |
802 | Ubiquitination | NLIYTYDKMKLKGSS CEEEEEECCCCCCCC | 27.76 | - | |
806 | Ubiquitination | TYDKMKLKGSSIQLS EEECCCCCCCCCCCC | 51.75 | 29967540 | |
808 | Phosphorylation | DKMKLKGSSIQLSDK ECCCCCCCCCCCCCH | 23.76 | 25690035 | |
815 | Ubiquitination | SSIQLSDKKLCQICQ CCCCCCCHHHHHHCC | 44.24 | 29967540 | |
816 | Ubiquitination | SIQLSDKKLCQICQN CCCCCCHHHHHHCCC | 60.53 | - | |
846 | Phosphorylation | VHTHCAASRHTNPSS EEEEECCCCCCCCCC | 13.18 | - | |
849 | Phosphorylation | HCAASRHTNPSSSSP EECCCCCCCCCCCCC | 47.95 | 28450419 | |
852 | Phosphorylation | ASRHTNPSSSSPGTR CCCCCCCCCCCCCCC | 44.94 | 21955146 | |
853 | Phosphorylation | SRHTNPSSSSPGTRT CCCCCCCCCCCCCCC | 35.77 | 21955146 | |
854 | Phosphorylation | RHTNPSSSSPGTRT- CCCCCCCCCCCCCC- | 44.91 | 25159151 | |
855 | Phosphorylation | HTNPSSSSPGTRT-- CCCCCCCCCCCCC-- | 29.33 | 25159151 | |
858 | Phosphorylation | PSSSSPGTRT----- CCCCCCCCCC----- | 34.22 | 28450419 | |
860 | Phosphorylation | SSSPGTRT------- CCCCCCCC------- | 42.68 | 28450419 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of TGFA1_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of TGFA1_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of TGFA1_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
SMAD4_HUMAN | SMAD4 | physical | 11278302 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-855, AND MASSSPECTROMETRY. |